Loading
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Oct 2026 for Lipocine Inc., €17k. Read the official filing
Filing timeline
BuySaleJohn W. Higuchi
Insider track record
Disclosed buys
6
Disclosed sells
0
Signal history
Closed purchases
Market purchases
5
Positive at T+90
100%
Median T+90
+19.7%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +16.0%Entry US$2.13 · Close at T+90 US$2.47
- +23.5%Entry US$2.00 · Close at T+90 US$2.47
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John W. Higuchi: trading record in brief
All filings by John W. Higuchi on record concern Lipocine Inc. We count 9 filings; the first trade dates from 12 May 2017 and the latest from 30 September 2026.
Every open-market trade on record is a purchase: 6 purchases worth €423k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 2 option exercises. So far in 2026, the count stands at 5 purchases and no sales.
The median purchase comes to €47k. Measured against the company's value, the median purchase equals 0.15% of market capitalisation, across 3 purchases where it is known. Clusters matter here: 2 out of 6 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
Most recently, on 1 October 2026, the filings show an open-market purchase worth €17k in Lipocine Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John W. Higuchi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
9,037 shares@ US$2.15Common stockSEC:0001493152-26-045400:0
Canonical exit: 28 Dec 2026 (T+90)
15,970 shares@ US$2.23Common stockSEC:0001493152-26-045400:1
Canonical exit: 29 Dec 2026 (T+90)
12,561 shares@ US$2.160.15% mcap7.6% of flowCommon stockSEC:0001493152-26-045185:0
Canonical exit: 27 Dec 2026 (T+90)
40,000 shares@ US$2.0324.1% of flowCommon stockSEC:0001493152-26-015583:0
Canonical exit: 6 Jul 2026 (T+90)
123,000 shares@ US$2.0575.9% of flowCommon stockSEC:0001493152-26-015361:0
Canonical exit: 5 Jul 2026 (T+90)
5 of 5 declarations
